FOLH1 and metastatic malignant neoplasm in the lymph nodes: PSMA-PET has a high specificity (95%) and positive predictive value (PPV; 87%) to detect lymph node metastases in high (specificity 93%, PPV 81%) and intermediate (specificity 96%, PPV 93%) risk patients [1, 2].